Safety analysis of liposomal doxorubicin-based adjuvant chemotherapy in breast cancer

MA Chuandong; BU Xiaoqiu; WANG Zhongrui

doi:10.3969/j.issn.1009-0460.2017.07.014

Abstract：Objective To evaluate the safety of liposomal doxorubicin-based regimen in postoperative adjuvant chemotherapy for breast cancer.Methods From September 2014 to August 2016,29 breast cancer patients were treated with liposomal doxorubicinbased adjuvant chemotherapy in our department.Fourteen patients were treated with 3 cycles of FAC (5-FU 500 mg/m2,liposomal doxorubicin 30 mg/m2,CTX 500 mg/m2,every 3 weeks);Eleven patients received 4 cycles of AC by a two-week program (liposomal doxorubicin 30 mg/m2,CTX 600 mg/m2,every 2 weeks);Four patients were treated with 4 cycles of AC by a three-week program (liposomal doxorubicin 30 mg/m2,CTX 600 mg/m2,every 3 weeks).The adverse events estimated by NCI CTCAE 4.0.3 criterion were divided into 1-5 levels.The cardiotoxicity was evaluated by examination of electrocardiogram and echocardiography periodically,and so on.Results The major hematological toxicity of 29 patients was neutropenia,and the incidence was about 79.3％ (23/29).Most common nonhematologic toxicities were hand-foot syndrome and oral mucotitis,and the incidence was about 51.7％ (15/29),27.6％ (8/29) respectively.The incidence of severe hand-foot syndrome (grade 3) in AC group was 26.7％ (4/15),higher than 0 (0/14) in FAC group (P＜0.05).There was no patient whose left ventricular ejection fraction (LVEF) deceased more than ten percent,and no patient with signs and symptoms of congestive heart failure during chemotherapy.Conclusion Liposomal doxorubicin-based adjuvant chemotherapy can be safe in the treatment of breast cancer.